Yersinia enterocolitica ghost with msbB mutation provides protection and reduces proinflammatory cytokines in mice

Vaccine

Volumn 31, Issue 2, 2013, Pages 334-340

  Cai, Kun ^a   Zhang, Yong ^a   Yang, Baoyu ^a   Chen, Shiyun ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

Bacterial ghosts (BGs); Lipopolysaccharide (LPS); MsbB; Yersinia enterocolitica

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROTEIN MSBB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; YERSINIA ENTEROCOLITICA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE MUTATION; GENE SEQUENCE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL TIME; WILD TYPE; YERSINIA ENTEROCOLITICA; YERSINIOSIS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; FEMALE; IMMUNOGLOBULIN G; INFLAMMATION; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-4; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; MUTATION; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA; YERSINIA ENTEROCOLITICA; YERSINIA INFECTIONS;

EID: 84871383993     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.004     Document Type: Article

References (39)

1. Bottone E.J. Yersinia enterocolitica: the charisma continus. Clin Microbiol Rev 1997, 10(2):257-276.
2. Cover T.L., Aber R.C. Yersinia enterocolitica. N Engl J Med 1989, 321(1):16-24.
3. Carniel E., Mollaret H.H. Yersiniosis. Comp Immunol Microbiol Infect Dis 1990, 13(2):51-58.
4. Long C., Jones T.F., Vugia D.J., Scheftel J., Strockbine N., Ryan P., et al. Yersinia pseudotuberculosis and Y. enterocolitica infections, FoodNet, 1996-2007. Emerg Infect Dis 2010, 16(3):566-567.
5. Cornelis G.R. Molecular and cell biology aspects of plague. Proc Natl Acad Sci U S A 2000, 97(16):8778-8783.
6. Roggenkamp A., Geiger A.M., Leitritz L., Kessler A., Heesemann J. Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Infect Immun 1997, 65(2):446-451.
7. Schmidt A., Schaffelhofer S., Müller K., Röllinghoff M., Beuscher H.U. Analysis of the Yersinia enterocolitica 0:8 V antigen for cross protectivity. Microb Pathog 1999, 26(4):221-233.
8. Branger C.G., Torres-Escobar A., Sun W., Perry R., Fetherston J., Roland K.L., et al. Oral vaccination with LcrV from Yesinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yesinia pseudotuberculosis and Yersinia enterocolitica. Vaccine 2009, 27(39):5363-5370.
9. Noll A., Autenrieth I.B. Immunity against Yersinia enterocolitica by vaccination with Yersinia HSP60 immunostimulating complexes or Yersinia HSP60 plus interleukin-12. Infect Immun 1996, 64(8):2955-2961.
10. Bühler O.T., Wiedig C.A., Schmid Y., Grassl G.A., Bohn E., Autenrieth I.B. The Yersinia enterocolitica invasion protein promotes major histocompatibility complexes class I- and class II-restricted T-cell responses. Infect Immun 2006, 74(7):4322-4329.
11. Kaneko K., Hashimoto N. Cross-resistance to fecal excretion of Yesinia enterocolitica in mice by oral vaccination of killed cells. Infect Immun 1983, 40(3):1223-1225.
12. Autenrieth S.E., Autenrieth I.B. Yersinia enterocolitica: subversion of adaptive immunity and implications for vaccine development. Int J Med Microbiol 2008, 298(1-2):69-77.
13. Li S.R., Dorrell N., Everest P.H., Dougan G., Wren B.W. Construction and characterization of a Yersinia enterocolitica 0:8 high-temperature requirement (htrA) isogenic mutant. Infect Immun 1996, 64(6):2088-2094.
14. Dorrell N., Li S.R., Everest P.H., Dougan G., Wren B.W. Construction and characterization of a Yersinia enterocolitica 0:8 ompR mutant. FEMS Microbiol Lett 1998, 165(1):145-151.
15. Di Genaro M.S., Waidmann M., Kramer U., Hitziger N., Bohn E., Autenrieth I.B. Attenuated Yersinia enterocolitica mutant strains exhibit differential virulence in cytokine-deficient mice: implications for the development of novel live carrier vaccines. Infect Immun 2003, 71(4):1804-1812.
16. Igwe E.I., Rüssmann H., Roggenkamp A., Noll A., Autenrieth I.B., Heesemann J. Rational live oral carrier vaccine design by mutating virulence-associated genes of Yersinia enterocolitica. Infect Immun 1999, 67(10):5500-5507.
17. Leibiger R., Niedung K., Geginat G., Heesemann J., Trülzsch K. Yersinia enterocolitica Yop mutants as oral live carrier vaccines. Vaccine 2008, 26(51):6664-6670.
18. Blanco H.M., Lacoste M.G., Eliçabe R.J., Di Genaro M.S. IgA response by oral infection with an attenuated Yersinia enterocolitica mutant: implications for its use as oral carrier vaccine. Vaccine 2008, 26(51):6497-6502.
19. Marchart J., Dropmann G., Lechleitner S., Schlapp T., Wanner G., Szostak M.P., et al. Pasteurella multocida- and Pasteurella haemolytica-ghosts: new vaccine candidates. Vaccine 2003, 21(25-26):3988-3997.
20. Eko F.O., Schukovskaya T., Lotzmanova E.Y., Firstova V.V., Emalyanova N.V., Klueva S.N., et al. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine 2003, 21(25-26):3663-3674.
21. Witte A., Wanner G., Bläsi U., Halfmann G., Szostak M., Lubitz W. Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E. J Bacteriol 1990, 172(7):4109-4114.
22. Felnerova D., Kudela P., Bizik J., Haslberger A., Hensel A., Saalmuller A., et al. T cell-specific immune response induced by bacterial ghosts. Med Sci Monit 2004, 10(10):BR362-BR370.
23. Galanos C., Lüderitz O., Rietschel E.T., Westphal O., Brade H., Brade L., et al. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem 1985, 148(1):1-5.
24. Cai K., Gao X., Li T., Hou X., Wang Q., Liu H., et al. Intragstric immunization of mice with enterohemorrhagic Escherichia coli O157:H7 bacterial ghosts reduces mortality and shedding and induces a Th2-typedominated mixed immune response. Can J Microbiol 2010, 56(5):389-398.
25. Low K.B., Ittensohn M., Le T., Platt J., Sodi S., Amoss M., et al. Lipid A mutant Salmonella with suppressed virulence and TNF alpha induction retain tumor-targeting in vivo. Nat Biotechnol 1999, 17(1):37-41.
26. Hu Y., Lu P., Wang Y., Ding L., Atkinson S., Chen S. OmpR positively regulates urease expression to enhance acid survival of Yersinia pseudotuberculosis. Microbiology 2009, 155(Pt8):2522-2531.
27. Gronow S., Brade H. Lipopolysaccharide biosynthesis: which steps do bacterial need to survive?. J Endotoxin Res 2001, 7(1):3-23.
28. McKelvie N.D., Khan S.A., Karavolos M.H., Bulmer D.M., Lee J.J., DeMarco R., et al. Genetic detoxification of an aroA Salmonella enterica serovar Typhimurium vaccine strain does not compromise protection against virulent Salmonella and enhances the immune responses towards a protective malarial antigen. FEMS Immunol Med Microbiol 2008, 52(2):237-246.
29. Alexander C., Rietschel E.T. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 2001, 7(3):167-202.
30. Pérez-Gutiérrez C., Llobet E., Llompart C.M., Reinés M., Bengoechea J.A. Role of lipid A acylation in Yersinia enterocolitica virulence. Infect Immun 2010, 78(6):2768-2781.
31. Khan S.A., Everest P., Servos S., Foxwell N., Zähringer U., Brade H., et al. A lethal role for lipid A in Salmonella infections. Mol Microbiol 1998, 29(2):571-579.
32. Mader H.J., Szostak M.P., Hensel A., Lubitz W., Haslberger A.G. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. Vaccine 1997, 15(2):195-202.
33. Białas N., Kasperkiewicz K., Radziejewska-Lebrecht J., Skurnik M. Bacterial cell surface structures in Yersinia enterocolitica. Arch Immunol Ther Exp (Warsz) 2012, 60(3):199-209.
34. Biedzka-Sarek M., Venho R., Skurnik M. Role of YadA, Ail, and lipopolysaccharide in serum resistance of Yersinia enterocolitica Serotype O:3. Infect Immun 2005, 73(4):2232-2244.
35. Kirjavainen V., Jarva H., Biedzka-Sarek M., Blom A.M., Skurnik M., Meri S. Yersinia enterocolitica serum resistance proteins YadA and ail bind the complement regulator C4b-binding protein. PLoS Pathog 2008, 4(8):e1000140.
36. Paerregaard A. Interactions between Yersinia enterocolitica and the host with special reference to virulence plasmid encoded adhesion and humoral immunity. Dan Med Bull 1992, 39(2):155-172.
37. Vogel U., Autenrieth I.B., Berner R., Heesemann J. Role of plasmid-encoded antigens of Yersinia enterocolitica in humoral immunityagainst secondary Y. enterocolitica infection in mice. Microb Pathog 1993, 15(1):23-36.
38. Raetz C.R. Biochemistry of endotoxins. Annu Rev Biochem 1990, 59:129-170.
39. Persing D.H., Coler R.N., Lacy M.J., Johnson D.A., Baldridge J.R., Hershberg R.M., et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 2002, 10(10 Suppl.):S32-S37.